Effect of the novel anxiolytic drug deramciclane on cytochrome P 450 2D6 activity as measured by desipramine pharmacokinetics

Background In vitro findings have indicated that the novel anxiolytic drug, deramciclane, is an inhibitor of the cytochrome P450 (CYP) 2D6 enzyme and co-administration of deramciclane and the CYP2D6 probe drug desipramine is possible in clinical practice.